What are the clinical implications of the preclinical data on oral semaglutide (RT-116) presented at ObesityWeek® 2025?

Rani Therapeutics' presentation of preclinical data on oral semaglutide (RT-116) at ObesityWeek® 2025 in November 2025 provides encouraging insights into the potential for a more convenient obesity treatment.1

Key Preclinical Findings for RT-116

The preclinical data for RT-116, delivered via the RaniPill® capsule, demonstrated several critical points:

• Comparable Efficacy: Oral RT-116 achieved bioavailability, pharmacokinetics, and weight loss comparable to the subcutaneous administration of semaglutide.2 This suggests that the RaniPill® effectively delivers the active pharmaceutical ingredient.
• Favorable Tolerability: The preclinical studies indicated that RT-116 was well tolerated, with no serious adverse events reported.2 This is a crucial factor for patient acceptance and long-term adherence.

Clinical Implications

These preclinical results carry significant clinical implications for the future treatment of obesity:

• Enhanced Patient Convenience and Adherence: The successful oral delivery of semaglutide could address common challenges associated with injectable medications, such as discomfort, needle anxiety, and potential adherence issues.3 An oral option with comparable efficacy could lead to higher patient compliance and, consequently, better treatment outcomes.
• Broader Accessibility: An oral formulation could make semaglutide-based therapies more accessible to a wider patient population, potentially simplifying administration outside of clinical settings.
• Platform Validation: This data further validates the RaniPill® platform's capability to orally deliver complex biologics and drugs, including other incretin-based molecules for obesity.2 Rani Therapeutics has also shown similar success with RT-114, a GLP-1/GLP-2 dual agonist.2

While these are preclinical findings, they lay a strong foundation for advancing RT-116 into human clinical trials. The ability to achieve comparable efficacy and safety to established injectable semaglutide via an oral route represents a potential paradigm shift in obesity management, offering a more patient-friendly alternative.

Compare the preclinical pharmacokinetic profile of RT-116 with publicly available data for other oral semaglutide formulations, such as Rybelsus.

Comparing the preclinical pharmacokinetic (PK) profile of Rani Therapeutics' oral semaglutide (RT-116) with publicly available data for other oral semaglutide formulations, such as Rybelsus, reveals distinct approaches and potential advantages.

RT-116 Preclinical Pharmacokinetic Profile

Rani Therapeutics has reported compelling preclinical data for RT-116, delivered via its RaniPill® HC capsule. These studies demonstrated that oral administration of RT-116 resulted in bioavailability, pharmacokinetics, and weight loss comparable to subcutaneous administration of semaglutide.1 This suggests that the RaniPill® platform is effective in delivering semaglutide in a manner that mimics injectable forms, which typically have 100% bioavailability. Furthermore, RT-116 was well tolerated in preclinical settings, with no serious adverse events observed.1 The RaniPill® platform has also shown similar success with other molecules, such as RT-114 (a GLP-1/GLP-2 dual agonist), which achieved a relative bioavailability of 111% compared to its subcutaneous counterpart in preclinical studies.1

Rybelsus Pharmacokinetic Profile

Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 receptor agonist for the treatment of type 2 diabetes and weight loss.2 Its oral formulation incorporates salcaprozate sodium (SNAC), an absorption enhancer that protects semaglutide from enzymatic degradation in the stomach and promotes its absorption.2 Despite this technology, the oral bioavailability of Rybelsus is known to be very low, typically less than 1%, and requires strict administration conditions (e.g., fasted state with a small amount of water, no other food or medication for 30 minutes) to optimize absorption.

Other companies are actively developing alternative oral semaglutide formulations that aim to improve upon Rybelsus's PK profile and tolerability. For instance, Lexaria Bioscience Corp. has developed a DehydraTECH-enhanced semaglutide formulation that, in human pilot studies, showed sustained higher levels of semaglutide in blood, faster achievement of peak drug delivery, and a significant reduction (43.5%) in gastrointestinal adverse events compared to Rybelsus.2 Similarly, Galmed Pharmaceuticals is exploring a sublingual semaglutide formulation that aims for enhanced bioavailability, reduced daily dosing, and a more consistent pharmacokinetic profile compared to Rybelsus.3

Comparative Outlook

The preclinical data for RT-116 indicate a potential for a significantly improved oral semaglutide experience. While Rybelsus offers an oral alternative to injections, its low bioavailability and stringent administration requirements present challenges. If RT-116's "comparable to subcutaneous" pharmacokinetic profile translates effectively into human clinical trials, it could represent a substantial advancement, offering a more convenient and potentially more effective oral option for patients, without the absorption limitations seen with current oral formulations like Rybelsus.

Compare the preclinical pharmacokinetic profile of RT-116 with publicly available data for other oral semaglutide formulations, such as Rybelsus.